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Abstract 26 
Purpose: The cross talk between tumour cells, myeloid cells, and T cells can play a 27 
critical role in tumour pathogenesis and response to immunotherapies. Although the 28 
aetiology of mesothelioma is well understood the impact of mesothelioma tumour cells 29 
on the surrounding immune microenvironment is less well studied. In this study the effect 30 
of the mesothelioma tumour microenvironment on circulating and infiltrating 31 
granulocytes and T cells is investigated.  32 
Experimental Design: Tumour tissues and peripheral blood from mesothelioma patients 33 
were evaluated for presence of granulocytes, which were then tested for their T cell 34 
suppression potential. Different co-cultures of granulocytes and/or mesothelioma tumour 35 
cells and/or T cells were set up to identify the mechanism of T cell inhibition. 36 
Results: Analysis of human tumours showed that the mesothelioma microenvironment is 37 
enriched in infiltrating granulocytes, which inhibit T cell proliferation and activation. 38 
Characterisation of the whole blood at diagnosis identified similar, circulating, 39 
immunosuppressive CD11b+CD15+HLADR- granulocytes at increased frequency 40 
compared to healthy controls. Culture of healthy-donor granulocytes with human 41 
mesothelioma cells showed that GM-CSF upregulates NOX2 expression and the release 42 
of Reactive Oxygen Species (ROS) from granulocytes, resulting in T cell suppression. 43 
Immunohistochemistry and transcriptomic analysis revealed that a majority of 44 
mesothelioma tumours express GM-CSF and that higher GM-CSF expression correlated 45 
with clinical progression. Blockade of GM-CSF with neutralising antibody, or ROS 46 
inhibition, restored T cell proliferation suggesting that targeting of GM-CSF could be of 47 
therapeutic benefit in these patients. 48 
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Conclusions: Our study presents the mechanism behind the cross-talk between 49 
mesothelioma tumours and the immune micro-environment and indicates that targeting 50 
GM-CSF could be a novel treatment strategy to augment immunotherapy in patients with 51 
mesothelioma.   52 
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Translational Relevance 53 
The functional role of granulocytes and their cross talk with tumour cells and T cells in 54 
human mesothelioma is not well understood. We demonstrated that GM-CSF is expressed by 55 
mesothelioma tumour cells, and can polarize granulocytes to up regulate ROS production which 56 
in turn suppresses the T cell proliferation and function. As GM-CSF plays a role in driving an 57 
immunosuppressive granulocyte phenotype in mesothelioma, targeting GM-CSF could 58 
represent an alternative therapeutic approach for these patients.  59 
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Introduction 60 
Malignant mesothelioma is an aggressive cancer arising from the mesothelial cells lining 61 
the pleura, peritoneum and pericardium (1). The majority of patients present with 62 
advanced stage disease and are not candidates for surgery. Although chemotherapy 63 
improves outcome for these patients, the median overall survival is less than 24 months 64 
(2). Immunotherapy approaches relying on T cell anti-cancer activity, such as peptide 65 
vaccines and CAR T cells, have shown only limited efficacy suggesting that the 66 
underlying immune microenvironment may play a role in muting the immune response 67 
(3, 4). 68 
Myeloid cells play an important role in the balance of pro- and anti- cancer T cell 69 
responses. Murine models of mesothelioma have shown that monocytes, macrophages, 70 
and dendritic cells may be modulated by the tumour microenvironment (5-7). However, 71 
the functional role of granulocytes and their mechanism of action in human mesothelioma 72 
is not well understood. Studies in mesothelioma have suggested the ratio between 73 
peripheral blood or intra-tumoural neutrophils and lymphocytes correlates with 74 
prognosis, indicating a key interaction between these cells in tumour pathogenesis (8). In 75 
other cancers, secreted factors within the tumour microenvironment control the 76 
differentiation of granulocytes. In turn this may promote inflammation within the tumour 77 
microenvironment or lead to changes in the interaction with the adaptive immune 78 
response. Here we investigate the mechanisms underlying the cross-talk between 79 
mesothelioma tumour cells, granulocytes and T cells. 80 
 81 
on May 3, 2018. © 2018 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757 
 7 
Materials and Methods 82 
Patients and sample collection 83 
Heparinized blood samples were obtained from patients with malignant mesothelioma 84 
(n=47) who were enrolled in IRB approved protocols at the National Cancer Institute, 85 
Bethesda, USA and the University of Birmingham, UK before treatment (Table S1). 86 
Written informed consent was obtained from all the patients and the study was conducted 87 
in accordance with recognized ethical guidelines. Blood from healthy donors was 88 
obtained from the NIH Blood Bank (n=30) and at the University of Birmingham, UK 89 
(n=18), in heparin tubes. Patients with both histologically confirmed pleural (n=24) and 90 
peritoneal (n=9) mesothelioma were included in this study and at the time of enrolment 91 
had clinical and/or radiological evidence of disease. A number of patients had received 92 
prior treatments including surgery and systemic chemo or immune-therapy (Table S1). 93 
The transcriptomes of 87 mesothelioma tumours diagnosed between 1999 and 2013, held 94 
within the R2: Genomics Analysis and Visualisation Platform (http://r2.amc.nl) were 95 
analysed for CSF2 expression. Patients were aged from 28 to 81 years of age at 96 
diagnosis. 56 patients had a history of asbestos exposure, 14 had no history, and 17 were 97 
not known. Of the 87 patients’ samples histologies were distributed as follows: 23 98 
biphasic, 5 diffuse, 57 epithelioid, 2 sarcomatoid. 99 
 100 
Cell lines 101 
Human mesothelioma cell lines (ED(MSTO211)-H, AC-Meso Y9-Meso, MPM15, 102 
MPM26, MPM30, MPM34, MPM43) purchased from the Aichi Cancer Research Centre 103 
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Institute and Mesobank UK were cultured in RPMI-1640 (Invitrogen) with 10% heat-104 
inactivated fetal bovine serum, glutamine (1X), sodium pyruvate (1X) and Penicillin-105 
Streptomycin (RPMI 10%=R10%). The cell lines were cultured in a humidified 106 
atmosphere at 37oC with 5% CO2. All cell lines were verified by Northgene (UK) DNA 107 
Short Tandem Repeat analysis within the last 6 months. All cell lines were tested of 108 
mycoplasma and were negative). Cell lines were used for up to 5 passages. 109 
 110 
Flow cytometric analysis of whole blood and tumours 111 
Whole blood and fresh tumour samples from diagnostic surgery were processed within 112 
12h of collection. 10 samples from patients with benign pleural pathologies of infectious 113 
and inflammatory nature were also included as a comparison. Whole blood was either 114 
lysed using ammonium chloride solution according to manufacturer’s instructions 115 
(Qiagen) or using a hypertonic ammonium chloride solution (150mM NH4Cl, 10mM 116 
KHCO3, 0.1mM EDTA) for 10 minutes at room temperature (maintained at 21-23oC) at a 117 
ratio of 1:9 (volume of sample: volume of lysing solution) prior to antibody staining. 118 
Where indicated peripheral blood was separated using a Lymphoprep density gradient. 119 
Tissue samples were digested using Type II collagenase (Worthington) for three hours at 120 
37°C. Immune populations were identified by staining with anti- CD11b, anti-HLA-DR, 121 
anti-CD13, anti-CD14, anti-CD15, anti-CD66b, and anti CD45 antibodies (BD 122 
Biosciences) on ice or at room temperature for 30minutes. Cells were acquired using 123 
FACS-Canto II (BD Biosciences) and Cyan (Beckman Coulter) and analysed either by 124 
FCS Express 4 software (DeNovo Software) or FlowJo (Tree Star). 125 
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 126 
Isolation of granulocytes, T cells, and mesothelioma cells for functional assays 127 
The whole blood from healthy donors and patients were processed as described above. 128 
We isolated the  low density granulocytes from the peripheral blood mononuclear layer 129 
and high density granulocytes from the layer of white cells on the red cell pellet, 130 
following Lymphoprep centrifugation, by magnetic bead isolation using anti-CD15 131 
microbeads (BD Pharmingen) and MACS LS separation columns (Miltenyi Biotech) 132 
according to manufacturer’s instructions. Cell purity was >98% as confirmed by flow 133 
cytometry. Cell populations were similarly isolated from collagenase digested tumours 134 
using MACS beads (anti-CD15 for granulocytes and anti-CD14 for monocytes), followed 135 
by flow cytometric confirmation of purity. The dose of collagenase selected has 136 
previously been established to not affect cell surface marker expression or cell viability. 137 
For isolation of autologous T cells and myeloid cells from the whole blood the target 138 
populations were enriched first using positive selection with CD45 magnetic beads 139 
(Miltenyi Biotech), followed by staining with myeloid antibodies (above) and anti-CD3 140 
antibody (Biolegend).  Cells were sorted on Astrios (Beckman Coulter) using a 100µm 141 
nozzle. DAPI was used as a viability marker to gate out the dead cells.  142 
 143 
Granulocyte polarisation 144 
To generate tumour conditioned media (TCM), cell lines or sorted patients’ tumour cells 145 
were plated (1.5 x 106 cells) and cultured for 72 hours. The conditioned media was 146 
removed and filtered prior to use. Following lymphoprep isolation high density 147 
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granulocytes were enriched by CD15 magnetic bead isolation as above, healthy donor 148 
granulocytes were plated in R10% in 24 well plates, at concentrations of 1x 106 per well. 149 
TCM was added as 25% of the total volume as indicated. Granulocytes were harvested 150 
following 24 hours of culture, washed twice prior to use in suppression assays. 151 
Granulocyte viability was confirmed to be >90% in all cases, by flow cytometry, before 152 
further experimentation. 153 
 154 
Autologous T-cell proliferation assays  155 
Sorted CD3+ T cells were labelled with 10µM carboxyfluorescein diacetate succinimidyl 156 
ester (CFSE; Life Technologies) and cultured with sorted granulocytes at ratios of 1:0, 157 
1:0.5, 1:1 in complete media at 37oC, 5% CO2 for 4 days in the presence of 1:1 ratio of 158 
anti-CD3/ anti-CD28 dynabeads (Invitrogen). Cells were stained with V450 anti-CD4 159 
(Clone-RPA-T4; BD Biosciences) and APC-Cy7 anti-CD8 (Clone-RPA-T8; BioLegend) 160 
and proliferation was determined by CFSE dilution. Unstimulated T cells were used as a 161 
negative control. The effect of the addition of L-NMMA (0.5mM, NG-Methyl-L-arginine 162 
acetate), nor-NOHA (0.5mM, N-Omega-hydroxy-nor-L-arginine) and iNAC (10mM) (all 163 
from Sigma Aldrich) was similarly tested. The percentage of cells that diluted CFSE 164 
(divided cells) was determined. 165 
 166 
Peripheral Blood Lymphocyte cell proliferation assay 167 
Peripheral blood lymphocytes (PBLs) (2 x 105) were cultured in 96 well flat bottom 168 
plates with coated anti-CD3 antibody (3μg/mL) and anti-CD28 antibody (2μg/mL), in 169 
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200μL R10%. Cells were incubated at 37oC, 5% CO2 for 4 days and then 1μCi/well 3H-170 
thymidine (Perkin Elmer Life Sciences) was added for 12-16 hours. 3H-thymidine 171 
incorporation was measured using a TopCount reader (Perkin Elmer). The suppressive 172 
ability of autologous or conditioned granulocytes was assessed by co-culturing purified 173 
cells together with the PBLs. nor-NOHA (0.5mM), L-NMMA (0.5mM), iNAC (10mM; 174 
Sigma Aldrich) was added to cells in culture. 25mM HEPES was added to the medium to 175 
maintain the pH after iNAC addition. Data are expressed as a percentage of PBL 176 
proliferation driven by antibody co-stimulation in the presence of MDSC, compared with 177 
PBL proliferation in the absence of suppressive cells (100%). 178 
 179 
Reactive Oxygen Species assay 180 
Sorted granulocytes were stained with 2’, 7’– dichlorofluorescein diacetate (DCFDA) 181 
using DCFDA cellular ROS detection assay kit (Abcam) for 30 minutes at 37oC. The 182 
stained cells were analyzed on a BD FACS Calibur and Cyan (Beckman Coulter). Cells 183 
stained with Tert-butyl hydrogen peroxide (TBHP), TCM polarized granulocytes were 184 
also incubated with Phorbol 12-myristate 13-acetate (PMA) (concentration need to be 185 
added) during the staining with DCFDA, this was used as a positive control.  186 
Quantification of H2O2 production was measured using the Amplex Red Hydrogen 187 
Peroxidase assay kit (Invitrogen). Following culture in mesothelioma conditioned media 188 
for 24 hours, sorted granulocytes were washed twice in R10%, counted and plated in 189 
Krebs–Ringer phosphate buffer, according to manufacturer’s guidelines. Detection of 190 
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H2O2 was carried out following 30 minutes of incubation at 37°C using a microplate 191 
reader at 560nm. 192 
 193 
ELISA 194 
The concentrations of cytokines within conditioned media following culture with T cells, 195 
mesothelioma cell lines (1x106/mL) or sorted tumour cells were quantified using a 196 
competitive enzyme linked immunoassay according to the manufacturers’ instructions. 197 
The following molecules were tested GM-CSF (Biolegend), IL-13 (BD Biosciences), IL-198 
8 (Biolegend), IL-6 (Biolegend), G-CSF (R&D Systems), VEGF (R&D Systems), 199 
Mesothelin (Biolegend).The concentration of IFN-γ in co-culture supernatants was 200 
determined by Ready Set Go ELISA kit (eBioscience). 201 
 202 
RT-Q-PCR analysis 203 
RT-Q-PCR was used to detect NOX2 expression in cell line supernatant conditioned 204 
granulocytes (0, 4, 8, 12, 24 hour time points). RNA was extracted using an RNeasy Mini 205 
kit (Qiagen). cDNA was prepared using SuperScriptTM III Reverse Transcriptase 206 
(Invitrogen, CA) following the manufacturer’s instructions. RT-Q-PCR was done in 207 
duplicate using FAST SYBR Green Master Mix (Applied Biosystems) and the Applied 208 
Biosystems 7500 Fast Real-Time PCR system. Analysis of gene expression was 209 
calculated according to 2-ΔT method and plotted as arbitrary units of mRNA relative to 210 
GAPDH. Gene specific primer sequences were NOX2 (CAAGATGCGTGGAAACTA, 211 
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F; TCCCTGCTCCCACTAACA, R) and GAPDH (CCAGCCGAGCCACATCGCTC, F; 212 
ATGAGCCCCAGCCTTCTC, R) (Eurofins). 213 
 214 
Immunohistochemistry 215 
Mesothelioma sections, from diagnostic tumour biopsies (n=38), were deparaffinised in 216 
Histoclear (National diagnostics) and ethanol, and rehydrated in 0.3% hydrogen peroxide 217 
for 15 minutes. Antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) 218 
for 20 minutes in a microwave oven. Slides were cooled and washed prior to blocking in 219 
5X Caesin (Thermofisher) for 30 minutes at room temperature. Sections were then 220 
incubated over night with primary antibody, rabbit anti-GM-CSF (Novus Biologicals), 221 
diluted in PBS. Sections were washed and secondary antibody (Universal ImmPRESS 222 
antibody, Vector Laboratories) was added at room temperature for 30 minutes, followed 223 
by further washing and addition of DAB substrate (ImmPACT DAB, Vector 224 
Laboratories) for 5 minutes. After counterstaining with Harris haematoxylin (Sigma), 225 
slides were dehydrated using ethanol and Histoclear and mounted using Omnimount 226 
(National diagnostics). Slides were examined and photographed using a Nikon Eclipse 227 
400 microscope. 228 
 229 
Statistical analysis 230 
Continuous parameter values were compared between two groups using an exact form of 231 
a Wilcoxon rank sum test. Paired comparisons were performed using a Wilcoxon signed 232 
rank test. Spearman correlation analysis was used to determine the correlation between 233 
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age and MDSC parameters. The correlations are interpreted as follow: strong if |r| >0.70; 234 
moderately strong if 0.50 < |r| <0.70; weak to moderately strong if 0.30 < |r| < 0.50; weak 235 
if |r| <0.30. All p-values are two-tailed and presented without adjustment for multiple 236 
comparisons because all tests performed were considered to be exploratory. 237 
 238 
Results 239 
Mesothelioma tumours modulate infiltrating myeloid cells to suppress T cell 240 
responses 241 
The immune microenvironment in mesothelioma has been shown to have strong 242 
prognostic implications, with infiltration by CD8+ lymphocytes conferring a favourable 243 
prognosis (9) and the association of peripheral blood granulocyte –to-lymphocyte ratio 244 
with poorer prognosis (10-12). However our understanding of the biological cross-talk 245 
between mesothelioma cells, granulocytes, and T cells in human patients is limited. 246 
Interrogation of the transcriptomic profile of 87 mesothelioma tumours, held within the 247 
R2: Genomics Analysis and Visualisation Platform (http://r2.amc.nl), suggested a 248 
significant infiltration of immune cells in the tumour microenvironment (Fig. 1a). Flow 249 
cytometric analysis of 18 digested, human mesothelioma tumours confirmed this data at 250 
the cellular level within the tumour microenvironment (Mean: CD15= 8.6%, CD14= 251 
4.8%, CD3=6.7%; Fig. 1b). Immuno-histochemical staining of a further 38 mesothelioma 252 
tumours supported the findings, with identification of granulocytes in all samples at 253 
diagnosis (Figure 1c). Characterisation of tumour-associated granulocytes by flow-254 
cytometry showed that they expressed CD11b, CD15, with low/absent CD33 expression, 255 
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and low/absent HLA-DR expression (Fig. 1d). Murine model of mesothelioma recently 256 
identified that the immune-regulatory transcriptome of granulocytes may be altered 257 
within the tumour microenvironment with potential effects on surrounding T cells and 258 
tumour cells.(13) To investigate the effects of granulocytes on T cells, CD15+ 259 
granulocytes were sorted from mesothelioma tumours at the time of resection, and co-260 
cultured with T cells from healthy donors. Tumour derived granulocytes suppressed T 261 
cell proliferation to a greater extent, compared to those from healthy donor blood or those 262 
extracted from pleural tissue with benign pathologies (Fig. 1e). Similarly CD14+ 263 
monocytes from mesothelioma tumours were sorted and also found to suppress T cell 264 
proliferation (p=0.0002) (Supplementary Fig. 1a). Therefore the tumour 265 
microenvironment is able to locally modulate infiltrating myeloid cells to inhibit T cell 266 
proliferation. 267 
 268 
Mesothelioma creates a systemic immunosuppressive environment through 269 
circulating granulocytes 270 
The effects of mesothelioma tumours on the immune system may be limited to the local 271 
tissue microenvironment or could also lead to systemic alteration. To test this we 272 
compared T cells from the blood of patients at diagnosis to those from healthy donors, 273 
and observed that mesothelioma patients’ T cells have a reduced proliferation capacity 274 
compared to those in healthy donors (Fig. 2a). We have previously identified that 275 
tumour-metabolism of arginine can create a systemic environment inhibitory to T cell 276 
responses. As mesotheliomas are known to be arginine auxotrophs, we measured the 277 
arginase activity of mesothelioma cell lines (14). No significant arginase activity was 278 
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identified suggesting an alternative mechanism must be responsible (Supplementary Fig. 279 
1b). As we identified immunosuppressive granulocytes infiltrating mesothelioma 280 
tumours, we therefore hypothesised the T cell suppression may be due to the presence of 281 
these circulating immunosuppressive myeloid cells. 282 
To investigate the hypothesis, the frequency of granulocytic and monocytic cells was 283 
characterised in the whole blood of healthy donors and mesothelioma patients (n=33) at 284 
diagnosis (Table S2). There were significant increases in the percentage of HLA-DR- 285 
granulocytes (CD14-CD15+CD11b+HLADR-) in the whole blood, compared to healthy 286 
controls (p=0.013) (Fig. 2b). Subpopulation analysis revealed only a marginal difference 287 
in HLA-DR- monocytes (CD14+CD15-CD11b+HLADR-) compared to healthy donors 288 
(p=0.05) (Figure 2c) and no difference in the frequency of HLA-DR+ monocytes 289 
(CD14+CD11b+HLADR+) (median 7.0% versus 8.9%; p=0.14) or HLA-DR+ granulocytes 290 
(CD15+CD14-CD11b+HLADR+ ) cells (median 0.83% vs. 1.46%; p=0.29) between 291 
healthy donors and mesothelioma patients. Consistent with reports of increased 292 
granulocyte:lymphocyte ratios in mesothelioma patients, granulocytes were the most 293 
predominant population overall (Median Frequency: CD14+ Monocytes-: 0.198% vs 294 
CD15+ Granulocytes- 66.8%). Immunophenotyping revealed significant differences in 295 
the relative expressions of granulocyte markers CD11b and CD66b compared to those 296 
from healthy donors (Fig. 2d and Supplementary Fig. 1c). 297 
As CD15+ granulocytes are the major population of circulating  myeloid cells in 298 
mesothelioma patients and shared the same immunophenotype as tumour-infiltrating 299 
granulocytes described above, their functional effects on T cells was examined further.  300 
Co-culture of sorted whole blood granulocytes from patients decreased both autologous 301 
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CD4+ and CD8+ T cell proliferation at ratios of 1:1 and1:0.5 (T cells:granulocytes) (Fig. 302 
2e and Supplementary Fig. 1d) and activation (p=0.0078, Fig. 2f). 303 
Immunosuppressive granulocytes may be methodologically identified in the PBMC layer 304 
(classical G-MDSC; low-density) and on the red cell pellet (high-density) following 305 
density gradient centrifugation of whole blood. Analysis of separated whole blood 306 
identified a significant increase in the frequency of granulocytes within the PBMC layer, 307 
however the frequency is extremely low (median <10%) with 90% of the granulocytes 308 
lying on the red cell pellet (Figure 3a). This small population of granulocytes had only a 309 
weak ability to suppress T cell proliferation (Fig. 3b). Only the high-density 310 
granulocytes, which had increased frequency in the patients, had suppressive activity 311 
(Figure 3b). Granulocytes from healthy donors had minimal effects on T cell proliferation 312 
(Fig. 1e and Supplementary Fig. 2a) or IFN- γ release (Supplementary Fig. 2b). Therefore 313 
granulocytes within the blood and tumours of mesothelioma patients share the same 314 
immunophenotype and functional capacity to suppress T cell proliferation and activation, 315 
thus extending the immunosuppressive microenvironment. 316 
 317 
Mesothelioma conditioned granulocytes suppress T cell proliferation by generation 318 
of reactive oxygen species 319 
Granulocytes can impair T cell proliferation through a number of mechanisms including 320 
arginine depletion, nitric oxide species or reactive oxygen species production, and release 321 
of immunosuppressive cytokines (15-19). We examined iNOS and Arginase I expression 322 
in patients’ granulocytes and those from healthy donors identifying no significant 323 
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differences in expression (Fig.3c). The addition of the Arginase or iNOS inhibitors, nor-324 
NOHA or L-NMMA respectively, to sorted patients’ granulocytes did not rescue T cell 325 
proliferation thus excluding these mechanisms. (Fig.3d). No evidence for 326 
immunosuppressive cytokine release from these cells was identified in patient plasma by 327 
ELISA (IL-10, IL-1β, IL-4, IL-13 Supplementary 2c). In a mesothelioma murine model 328 
Reactive Oxygen Species have been demonstrated to suppress T cell responses (20). 329 
Gating on granulocytes identified that mesothelioma patients’ upregulate ROS, compared 330 
to healthy controls (p=0.03; Fig. 3e, Supplementary Fig. 2d). Addition of the ROS 331 
inhibitor iNAC, to sorted patients’ granulocytes restored both autologous CD4+ and CD8+ 332 
T cells proliferation (Fig. 3f and Supplementary Fig. 2e) and IFN- release (Fig. 3g). We 333 
confirmed that ROS production was reduced by the addition the inhibitor iNAC 334 
(p=0.031, Fig. 3h). PDL1 is another mechanism that myeloid cells may use to modulate T 335 
cells. There was no significant difference in the frequency of CD15+PDL1+ cells in the 336 
blood or tumours of patients compared to those from healthy controls (Supplementary 337 
Fig. 2f). Correlating the frequency of PDL1+CD15+ cells with CD3+ frequency revealed 338 
no significant correlation in the blood (p=0.4976, r=-0.3214) (Supplementary Figure 2f), 339 
but there was a significant correlation in the tumour  (p=0.0583, r=0.8286) 340 
(Supplementary Fig 2g and h). The findings suggest that in the tumour, granulocyte 341 
PDL1 may be a secondary mechanism of modulating T cell numbers inside the tumour 342 
microenvironment, but not peripherally. 343 
 344 
GM-CSF from mesothelioma tumour cells drives granulocyte ROS production 345 
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Although it is recognised that mesothelioma tumours release G-CSF, which may 346 
contribute to granulocyte expansion and recruitment, the mechanism by which 347 
granulocytes are polarised to upregulate ROS production and suppress T cells is unknown 348 
(21, 22). Granulocytes produce reactive oxygen specifies through the activity of NADPH 349 
oxidase enzyme (NOX2) expression. Consistent with this we demonstrated NOX2 is 350 
expressed in patients’ granulocytes and healthy donors (Fig. 4a). To examine the effect of 351 
the mesothelioma microenvironment on granulocytes, healthy-donor derived 352 
granulocytes were cultured in the conditioned supernatants of mesothelioma cell lines or 353 
primary tumours. Conditioned supernatants led to an upregulation of NOX2 expression 354 
over time (Fig. 4b), with accompanying increase in the production (Figure 4c, 355 
Supplementary Fig. 3a and 3b) and release of reactive oxide species (Fig. 4d). PMA was 356 
used as positive control for ROS induction in granulocytes upregulation, confirming the 357 
mesothelioma specific mechanism (Supplementary Fig. 3c). The mesothelioma-358 
conditioned granulocytes showed a strong ability to suppress T cell proliferation (Figure 359 
4e), which could be rescued by the addition of iNAC (Fig. 4f). LOX-1 has been reported 360 
to be a marker for some granulocytic MDSCs (23). Conditioned media led to no change 361 
in LOX-1 on healthy donor granulocytes (Supplementary 3d). Therefore mesothelioma 362 
cells signal to granulocytes to modulate their function. 363 
To identify the nature of the mesothelioma-granulocyte cross-talk, mesothelioma 364 
conditioned supernatant was first boiled to denature all proteins. Boiled supernatant lost 365 
the ability to polarise granulocytes to suppress T cell proliferation (Supplementary Figure 366 
3e) consistent with the release of a soluble molecule from the mesothelioma cells. 367 
Arginine depletion, a potential mechanism of polarisation due to mesothelioma arginine 368 
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auxotrophism, similarly did not polarize healthy donor granulocytes to produce ROS 369 
consistent with this finding (Supplementary 3f). 370 
ELISAs for cytokines involved in granulocyte signalling were performed of supernatants 371 
from mesothelioma cell lines and mesothelioma human primary tumour cells, identified a 372 
number of key molecules were highly expressed – G-CSF, GM-CSF, IL-13, IL-6, IL-8, 373 
VEGF, PGE2, Mesothelin, (Fig. 5a). In particular mesothelioma cells release IL-8 374 
(neutrophil chemotactic protein; mean concentration 981pg/ml) and G-CSF (mean 375 
concentration 283pg/ml) which are known to attract granulocytes into the tumour 376 
microenvironment. No evidence of serum amyloid-A release from mesothelioma cells 377 
was found. Interrogation of the R2 database confirmed a similar cytokine expression 378 
profile from 87 human tumours (Fig. 5b). Culture of healthy-donor granulocytes with 379 
individual recombinant cytokines identified above, showed that GM-CSF led to the 380 
highest upregulation of ROS production (Fig. 5c) with associated upregulation in NOX2 381 
expression (Supplementary Fig. 3g). Granulocytes treated with recombinant GM-CSF 382 
inhibited T cell proliferation (Fig. 5d and 5e), and T cell proliferation was rescued by the 383 
inhibitor (iNAC) or removal of reactive oxygen species with catalase (Fig. 5e). No 384 
increases in plasma GM-CSF concentrations are identified in patients at diagnosis, 385 
suggesting that the intra-tumoural release of GM-CSF drives the ROS upregulation in 386 
granulocytes. (Supplementary Fig. 4a) Addition of anti-GM-CSF neutralising antibody to 387 
mesothelioma cell line co-cultures inhibited ROS upregulation (Fig. 6a and 6b) and the 388 
release of peroxide species in conditioned granulocyte supernatants (Supplementary Fig 389 
4b) confirming mesothelioma-released GMCSF drives granulocyte ROS production and 390 
T cell suppressive activity. The addition of anti-GM-CSF neutralising antibody rescued T 391 
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cell proliferation, confirming the mechanism of mesothelioma polarisation of 392 
granulocytes (Fig. 6c). 393 
ROS production from conditioned healthy granulocytes correlated with the concentration 394 
of GM-CSF in tumour conditioned media (r=0.438, p=0.0118) (Fig. 6d). 395 
Immunohistochemistry of  mesothelioma tumours confirmed that GM-CSF is expressed 396 
within the tumour microenvironment of patients (Fig. 6e and Supplementary Fig. 4c) and 397 
transcriptomic analysis of 87 primary tumour samples within the R2: database 398 
demonstrated that GM-CSF is expressed in over 50 % of the samples, and does not 399 
correlate with histological subtype (Fig. 6f). 400 
In summary mesothelioma creates an immunosuppressive microenvironment locally and 401 
systemically through the release of GM-CSF from tumour cells which induces 402 
granulocyte ROS production to inhibit T cell function. 403 
 404 
Discussion 405 
Although the role of monocytes and macrophages in mesotheliomas has previously been 406 
well documented in human tissue and murine models, granulocytes have received little 407 
attention. In this study we focused on human mesotheliomas, identifying the mechanism 408 
by which tumour cells modulate granulocyte function to suppress T cell responses.  A 409 
previous immune-histochemical study identified that high CD4 T cell counts or low 410 
neutrophil counts within mesothelioma tumours are linked to better patient outcomes 411 
(24). To evaluate the seemingly reciprocal relationship between granulocytes and T 412 
lymphocytes we first confirmed that granulocytes make up a significant proportion of 413 
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infiltrating immune cells, with relatively fewer T cells. To date granulocyte function in 414 
mesotheliomas has almost exclusively been studied in murine cell line xenografts. 415 
Murine granulocytes may be alternatively activated in mesotheliomas (N1 vs N2) or 416 
characterised as granulocytic MDSCs (G-MDSC) (13, 20, 25). In all of these murine 417 
cases the granulocytic cells express reactive oxide species – a well-established 418 
mechanism of T cell suppression (26). We carefully considered whether our tumour-419 
infiltrating and circulating granulocytes could be G-MDSC according to recent guidelines 420 
for nomenclature which define MDSCs based on immunophenotype, density, and 421 
suppressive activity (27). In our mesothelioma patients both circulating and tumour-422 
associated granulocytes were CD11b+CD14-CD15+/ CD66b+, fitting with the G-MDSC 423 
phenotype. However blood G-MDSCs are classically described as being low density 424 
cells, following separation with density centrifugation. We showed that in mesothelioma 425 
patients’ blood, low density granulocytes are a minority population within the PBMC 426 
layer and have minimal T cell suppressive activity – thus the two populations are distinct. 427 
In addition no evidence of altered LOX-1 expression, a marker recently identified on low 428 
density G-MDSCs, was found after mesothelioma conditioning of healthy donor 429 
granulocytes (23). The most suppressive granulocytes are those of high density, and act 430 
through ROS release. The intra-tumoural granulocytes we studied share the same 431 
immunophenotype and suppressive mechanism. As discussed in the consensus 432 
recommendations based on current technology there is no unique marker to distinguish 433 
suppressive granulocytes from G-MDSC, particularly for intra-tumoural cells. Notably 434 
the need to use cell density on separation as a method to define immune cell subsets is 435 
extremely limited, and alternative methodologies will be developed for the future 436 
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characterisation of these cells. Our findings highlight the plasticity of granulocytes in 437 
humans and their place in regulating the tumour associated immune microenvironment 438 
(13). Similar examples of human cancer-associated, immunosuppressive granulocytes, as 439 
opposed to G-MDSC, have been identified in melanoma and non-small lung cancer, 440 
driven through the release of tumour derived factors (15, 28).   441 
Our analysis of the supernatants of mesothelioma cell lines and primary tumor tissue 442 
revealed a cytokine profile consistent with granulocyte attraction and modulation within 443 
the tumor microenvironment. A number of factors have been reported to modulate 444 
granulocyte function in murine models of mesothelioma. In a murine model of 445 
mesothelioma, prostaglandin inhibition reduced the number of granulocytic MDSCs (20). 446 
TGF-beta within murine mesothelioma tumors also drives the expression of the 447 
chemokines CCL3, CCL5, and CCL2 in pro-tumoral granulocytes (29). For humans no 448 
direct mechanism of mesothelioma modulation of granulocytes has been shown  although 449 
the mesothelioma inducing mineral erionite can directly stimulate ROS production in 450 
healthy donor-derived neutrophils (30). IL-8 (CXCL8) is a potent pro-inflammatory 451 
cytokine and is primarily known for its chemotactic and activating action on neutrophils, 452 
along with inhibition of normal neutrophil apoptosis (31-33). Our finding of moderate 453 
levels of IL-8 released from mesothelioma cells, may contribute to the enhanced 454 
granulocytes infiltration of mesothelioma tumours.. Targeting of IL-8 in models of 455 
tumours such as fibrosarcoma and prostate carcinoma prevents the influx of host 456 
neutrophils (34). IL-8 is also an autocrine growth factor in a number of cancer types (35-457 
37), including mesothelioma (38).  458 
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We identified that meostheliomas can also release G-CSF, a second well established 459 
cytokine that induces granulocyte infiltration. Notably G-CSF production by 460 
mesothelioma is reported to confer a more aggressive phenotype (39-41).Although we 461 
confirmed mesothelioma tumours release IL-8 and G-CSF or prostaglandins, these 462 
factors had no impact in generating suppressive granulocytes. Instead we demonstrated 463 
that GM-CSF is expressed by mesothelioma tumor cells, and can polarize granulocytes to 464 
upregulate ROS productio . No differences in the effect of granulocyte derived ROS was 465 
found on CD4+ versus CD8+ T cells.Establishment of cell lines from primary 466 
mesotheliomas have reported significant production of GM-CSF (42) and this cytokine 467 
can  drive  suppressive granulocyte activity in murine models for a number of solid 468 
tumors (43-45). Although we identified GM-CSF was widely expressed in our samples 469 
studied, the effects of prior therapies in our patient population, on GM-CSF expression is 470 
unknown. 471 
Clinically GM-CSF has been used as an alternative to G-CSF to support myeloid cell 472 
recovery post-chemotherapy in mesothelioma patients (46, 47). No differences in 473 
outcome were reported for the two growth factors, although the effects on immune 474 
parameters are not available. Recombinant GM-CSF has also been administered 475 
alongside a tumor vaccine in this patient group (48-50) and used alongside 476 
immunotherapy approaches in neuroblastoma. In the mesothelioma studies GM-CSF was 477 
administered to patients in all study arms, regardless of whether they received the 478 
investigational tumour/peptide vaccines or not. Although responses are noted, it is not 479 
possible to understand whether the cytokine had any effect on outcomes both within the 480 
trial populations or compared to historical controls. It is possible that administration of 481 
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GM-CSF may inhibit anti-tumor T cell responses, through the induction of G-MDSC, 482 
contributing to the lack of clinically relevant T cell responses seen in these patients. In 483 
two trials where GM-CSF was administered intra-lesionally to mesothelioma, neutrophil 484 
infiltration and maturation was enhanced, however, this was not associated with tumor 485 
responses in the majority of patients (51, 52). Indeed a Phase II clinical trial in 486 
neuroblastoma demonstrated difference in prognosis if GM-CSF is administered 487 
intravenously vs subcutaneously, which could impact the dose-dependent effects of this 488 
cytokine on granulocyte phenotype (53, 54). 489 
Preclinical studies which block GM-CSF have resulted in reversal of T cell inhibition by 490 
MDSCs in the setting of pancreatic tumours, and improvements in phenotype in 491 
inflammatory disease models (55, 56). Our data suggests that targeting the GM-CSF 492 
pathway may be of benefit in mesothelioma. Clinically relevant approaches to target GM-493 
CSF have been focused on inflammatory diseases (57). Mavrilimumab (CAM-3001) is a 494 
human anti-GM-CSF receptor-a antibody which has completed Phase I and II clinical 495 
trials in the setting of rheumatoid arthritis (58). Our findings suggest that anti-GM-CSF 496 
or anti-GM-CSF receptor antibodies could play a critical role in mesothelioma treatment, 497 
particularly alongside T cell immunotherapies. 498 
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Figure Legends 683 
Figure 1. Granulocytes in tumor tissue suppress T cell proliferation. a) 684 
Transcriptomic expression of CD14, CD15, CD3E, and Mesothelin in 87 mesothelioma 685 
tumours from the R2: Genomics Analysis and Visualisation Platform (http://r2.amc.nl). 686 
b) Percentages of CD15
+
, CD14
+
, and CD3
+
cells detected by flow cytometry in the 687 
digested tumor tissue of 18 patients with confirmed mesothelioma. c) Representative 688 
tumor sections from 6 patients (total stained = 38 tumours) demonstrating infiltration of 689 
CD15 expressing cells within mesothelioma tumours. Images were taken at 20X 690 
magnification. d) Immunophenotype of tumour-associated granulocytes by flow-691 
cytometry identified they expressed CD11b, CD15, with low/absent CD33 expression, 692 
and low/absent HLA-DR expression. e) T cell proliferation from healthy donors is 693 
suppressed following culture with CD15+ granulocytes (representative 1:0.5 ratio) sorted 694 
from mesothelioma tumours, compared to those cultured in complete media alone, with 695 
CD15+ granulocytes from the blood of healthy donors, or from pleural tissue with benign 696 
pathologies. 697 
 698 
Figure 2. Granulocytes are elevated in peripheral blood of mesothelioma patients 699 
and suppress T cell proliferation and activation a) Sorted CD3+ T cells from the blood 700 
of mesothelioma patients (6 untreated, 2 with prior therapy) have reduced proliferative 701 
capacity compared to those sorted from the blood of healthy donors. b) Increased 702 
frequency of CD15+ granulocytes in the peripheral blood of mesothelioma patients 703 
(n=33) and healthy donors (n=30) at diagnosis. c) Marginal increased frequency of 704 
CD14+HLADR- monocytes in the peripheral blood of mesothelioma patients (n=33) and 705 
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healthy donors (n=30). d) Expression of CD15, CD16, CD11b, and CD66b markers on 706 
granulocytes of healthy donors and mesothelioma patients, as detected by flow 707 
cytometry. e) Autologous CD4+ and CD8+ T cell proliferation is suppressed following 708 
culture with CD15+ granulocytes sorted from the blood of patients at diagnosis. T cells 709 
and granulocytes were co-cultured at ratios of 1:0.5 and 1:1 respectively and compared to 710 
T cells alone (1:0). f) T cell-derived IFN-γ release in culture supernatants is significantly 711 
impaired following co-culture with CD15+ granulocytes sorted from the blood of patients 712 
at diagnosis. 713 
 714 
Figure 3. Granulocytes from mesothelioma patients suppress T cell proliferation 715 
through ROS a) The frequency of CD11b+CD15+ cells was compared in the whole blood 716 
and PBMC layer following Lymphoprep separation, for 18 mesothelioma patients and 12 717 
healthy donors. The majority of CD15+ granulocytes lie on the red cell pellet following 718 
lymphoprep separation. b) Healthy donor T cell proliferation is most suppressed 719 
following culture in the presence of blood CD15+ granulocytes from mesothelioma 720 
patients which have been collected from the red cell pellet (High Density) after 721 
Lymphoprep separation. Low density granulocytes isolated in the PBMC layer of the 722 
same blood samples were comparatively less suppressive to T cell proliferation. c )QPCR 723 
analysis of the expression of iNOS and Arginase in granulocytes sorted from healthy 724 
donors or patients d) T cell proliferation is not restored by the addition of L-NMMA or 725 
nor-NOHA to the cultures in the presence of CD15+ granulocytes from patients. 2 726 
representative patients are shown. e) Increased frequency of ROS+ CD15+ granulocytes in 727 
the blood of patients from mesothelioma patients compared to healthy donors f) 728 
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Inhibition of NOX2 activity with iNAC reversed the suppressive effect of granulocytes 729 
on CD4 and CD8 T cell proliferation. g) Inhibition of NOX2 activity with iNAC restored 730 
T cell activation, as measured by IFN- release into cell supernatants. h) Culture of 731 
patients’ granulocytes with iNAC reduced the intracellular production of ROS confirming 732 
the known specificity of drug action. 733 
 734 
Figure 4. ROS generation by granulocytes is upregulated by the mesothelioma 735 
microenvironment a) Expression of NOX2 by qRT-PCR in CD15+ cells from the blood 736 
of healthy donors and mesothelioma patients. b) NOX2 expression in CD15+ 737 
granulocytes is upregulated over time following co-culture with mesothelioma cell lines, 738 
as assessed by qRT-PCR. c) ROS production is up-regulated in healthy-donor derived 739 
granulocytes following culture in conditioned media from sorted mesothelioma malignant 740 
cells or mesothelioma cell lines, compared to complete RPMI. ROS species are detected 741 
by DCFDA staining and flow cytometry. d) Release of ROS from CD15+ granulocytes is 742 
upregulated after culture with mesothelioma cell lines or sorted mesothelioma malignant 743 
cells as detected by hydrogen peroxide species, using a colorimetric assay. e) T cell 744 
proliferation is significantly inhibited following culture with cell line conditioned- or 745 
tumour conditioned- granulocytes. Comparison made with T cells cultured with 746 
granulocytes conditioned by completed media alone. f) Treatment of mesothelioma cell 747 
line conditioned granulocytes with iNAC prevents suppression of T cell proliferation 748 
 749 
 750 
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Figure 5: Mesothelioma cells release GM-CSF to up-regulate granulocyte ROS and 751 
suppressive activity a) Cytokine multiplex assay determined the cytokine profile of 752 
tumor cell supernatants and cell line supernatants. Increased concentrations of GM-CSF, 753 
IL-8, GCSF, VEGF, IL-6 and mesothelin are found. Low concentrations of prostaglandin 754 
E2 and IL-13 were detected. b) Transcriptomic expression of GMCSF, GCSF, IL-6, IL-755 
13, IL-8, VEGF, and mesothelin in 87 mesothelioma tumours from the R2: Genomics and 756 
Visualisation Platform c) ROS production (DCFDA staining) by healthy donor CD15+ 757 
cells treated with detected cytokines to determine which were capable of enhancing ROS 758 
production. GM-CSF increased ROS production most prominently. d) T cell proliferation 759 
was significantly suppressed by granulocytes conditioned with recombinant GM-CSF, 760 
compared to control granulocytes. Ratios of 1:1 and 1:0.5 T cells:granulocytes shown e) 761 
Inhibition of granulocyte ROS production (iNAC) or accumulation (catalase) after 762 
healthy donor granulocytes were conditioned with GM-CSF, restores T cell proliferation 763 
compared to controls. 764 
 765 
Figure 6: Anti-GM-CSF neutralizing antibody can prevent granulocyte suppressive 766 
function a) The addition of anti-GM-CSF neutralizing antibody to mesothelioma cell line 767 
conditioned media prevents granulocyte ROS expression, as measured by DCFDA 768 
staining. Representative histograms for ED cell line shown. b) The addition of anti-GM-769 
CSF neutralizing antibody to mesothelioma cell line conditioned media prevents 770 
granulocyte ROS expression. Geometric means for DCFDA staining shown following 771 
flow cytometric detection. c) The addition of anti-GM-CSF neutralizing antibody to 772 
mesothelioma cell line conditioned media, prevents granulocyte suppressive activity 773 
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compared to granulocytes cultured in tumour-conditioned media alone. d) Correlation 774 
between GM-CSF concentrations in tumour conditioned media and expression of 775 
Reactive Oxygen Species in conditioned granulocytes, as measured by DCFDA mean 776 
fluorescence intensity by flow cytometry. Linear correlation line shown. e)  777 
Immunohistochemistry staining demonstrating the presence of GM-CSF in mesothelioma 778 
tumor sections. Mesothelioma of epithelioid (first image), adenomatoid (second and third 779 
images) and mixed/biphasic (fourth image) type demonstrated cytoplasmic positivity of 780 
tumor cells in a diffuse pattern. Images taken at 20 X magnification. (f) Interrogation of 781 
87 primary tumor samples within the R2: database demonstrated that GM-CSF is 782 
expressed in over 50 % of the samples, and did not correlate with histological subtype. 783 
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